{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-124563","form_type":"8-K","ticker":"NMRA","cik":"0001885522","company_name":"Neumora Therapeutics, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.249754+00:00","generated_at":"2026-05-30T02:17:51.232438+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Neumora Q3 net loss $72.5M; cash $341.3M; Ph3 MDD data around end-2024","bullets":["Cash and marketable securities $341.3M; operations funded into mid-2026.","Q3 R&D expenses $60.6M (vs $41.6M YoY); net loss $72.5M (vs $53.0M).","Phase 3 KOASTAL-1 navacaprant topline data expected around end of 2024.","KOASTAL-2/3 topline data H1 2025; navacaprant Phase 2 bipolar depression data H2 2025.","NMRA-511 Phase 1b AD agitation data H2 2025; M4 PAM IND submission expected H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-124563","json":"https://secwatch.observer/filing/0000950170-24-124563.json","markdown":"https://secwatch.observer/filing/0000950170-24-124563.md","text":"https://secwatch.observer/filing/0000950170-24-124563.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1885522/000095017024124563/0000950170-24-124563-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1885522/000095017024124563/nmra-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:17:51.232438+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}